A survey of CMV prevention strategies after liver transplantation

American Journal of Transplantation

Volumn 8, Issue 1, 2008, Pages 158-161

  Levitsky, J ^a   Singh, N ^b   Wagener, M M ^b   Stosor, V ^a   Abecassis, M ^a   Ison, M G ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cytomegalovirus (CMV); Liver transplantation; Preemptive antiviral therapy; Prophylaxis

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CYTOMEGALOVIRUS ANTIBODY; FAMCICLOVIR; GANCICLOVIR; VALACICLOVIR; VALGANCICLOVIR;

ARTICLE; CANADA; CYTOMEGALOVIRUS INFECTION; HUMAN; INFECTION PREVENTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; UNITED STATES;

ANTIVIRAL AGENTS; CANADA; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HEALTH CARE SURVEYS; HUMANS; LIVER TRANSPLANTATION; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; UNITED STATES; VIREMIA;

EID: 37549030568     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2007.02026.x     Document Type: Article

References (15)

1. Rubin RH. Cytomegalovirus infection in the liver transplant recipient. Epidemiology, pathogenesis, and clinical management. Clin Liver Dis 1997 1 : 439 452.
2. Winston DJ, Emmanouilides C, Busuttil RW. Infections in liver transplant recipients. Clin Infect Dis 1995 21 : 1077 1089.
3. Singh N. Cytomegalovirus infection in solid organ transplant recipients: New challenges and their implications for preventive strategies. J Clin Virol 2006 35 : 474 477.
4. Avery RK, Adal KA, Longworth DL, Bolwell BJ. A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and preemptive therapy. Bone Marrow Transplant 2000 26 : 763 767.
5. Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004 4 : 611 620.
6. Humar A, Paya C, Pescovitz MD et al. Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients. Am J Transplant 2004 4 : 644.
7. Sia IG, Wilson JA, Groettum CM, Espy MJ, Smith TF, Paya CV. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 2000 181 : 717 720.
8. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005 143 : 870 880.
9. Singh N, Wannstedt C, Keyes L, Wagener MM, Gayowski T, Cacciarelli TV. Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C virus sequelae, and mortality) in liver-transplant recipients with the use of preemptive therapy for 13 years. Transplantation 2005 79 : 1428 1434.
10. Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: Impact on viral load and late-onset cytomegalovirus disease. Transplantation 2005 79 : 85 90.
11. Diaz-Pedroche C, Lumbreras C, San Juan R et al. Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients. Transplantation 2006 82 : 30 35.
12. Khoury JA, Storch GA, Bohl DL et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006 6 : 2134 2143.
13. Limaye AP, Bakthavatsalam R, Kim HW et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006 81 : 1645 1652.
14. Park JM, Lake KD, Arenas JD, Fontana RJ. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. Liver Transpl 2006 12 : 112 116.
15. Clark BS, Chang IF, Karpen SJ et al. Valganciclovir for the prophylaxis of cytomegalovirus disease in pediatric liver transplant recipients. Transplantation 2004 77 : 1480.